{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T12:06:28Z","timestamp":1749729988339,"version":"3.40.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/143669\/2019","2020.08932.BD","10.54499\/DL57\/2016\/CP1363\/CT0012","10.54499\/UIDP\/04501\/2020","DOI 10.54499\/DL57\/2016\/CP1457\/CT0013","10.54499\/CEECIND\/03906\/2017\/CP1421\/CT0004","DOI: 10.54499\/2021.01550.CEECIND\/CP1663\/CT0012"],"award-info":[{"award-number":["SFRH\/BD\/143669\/2019","2020.08932.BD","10.54499\/DL57\/2016\/CP1363\/CT0012","10.54499\/UIDP\/04501\/2020","DOI 10.54499\/DL57\/2016\/CP1457\/CT0013","10.54499\/CEECIND\/03906\/2017\/CP1421\/CT0004","DOI: 10.54499\/2021.01550.CEECIND\/CP1663\/CT0012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA228272, U54CA268084, and U54CA261694"],"award-info":[{"award-number":["R01CA228272, U54CA268084, and U54CA261694"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["EFMA1830961"],"award-info":[{"award-number":["EFMA1830961"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ipatimup","award":["MSI project and CancerChallenge2022"],"award-info":[{"award-number":["MSI project and CancerChallenge2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94549-2","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:55:15Z","timestamp":1745499315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differential unfolded protein response regulation in KRAS silencing sensitive and innately resistant colorectal cancer cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Fl\u00e1via","family":"Martins","sequence":"first","affiliation":[]},{"given":"Ana L.","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Catarina R.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Hans C.","family":"Beck","sequence":"additional","affiliation":[]},{"given":"Ana S.","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Vadim","family":"Backman","sequence":"additional","affiliation":[]},{"given":"Rune","family":"Matthiesen","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgia","family":"Velho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"94549_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/304507a0","volume":"304","author":"DJ Capon","year":"1983","unstructured":"Capon, D. J. et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304, 507\u2013513 (1983).","journal-title":"Nature"},{"key":"94549_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/304497a0","volume":"304","author":"K Shimizu","year":"1983","unstructured":"Shimizu, K. et al. Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1. Nature 304, 497\u2013500 (1983).","journal-title":"Nature"},{"key":"94549_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/300539a0","volume":"300","author":"S Pulciani","year":"1982","unstructured":"Pulciani, S. et al. Oncogenes in solid human tumours. Nature 300, 539\u2013542 (1982).","journal-title":"Nature"},{"key":"94549_CR4","doi-asserted-by":"crossref","unstructured":"Der, C. J., Krontiris, T. G. & Cooper, G. M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. 79, 3637\u20133640 (1982).","DOI":"10.1073\/pnas.79.11.3637"},{"key":"94549_CR5","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.critrevonc.2023.104250","volume":"194","author":"Y Chhichholiya","year":"2024","unstructured":"Chhichholiya, Y., Singh, H. V., Vashistha, R., Singh, S. & Munshi, A. Deciphering the role of KRAS gene in oncogenesis: focus on signaling pathways, genetic alterations in 3\u2032UTR, KRAS specific MiRNAs and therapeutic interventions. Crit. Rev. Oncol. Hematol. 194, 104250 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"94549_CR6","doi-asserted-by":"crossref","unstructured":"Haigis, K. M. KRAS alleles: The devil is in the detail. Trends Cancer 3, 686\u2013697 (2017).","DOI":"10.1016\/j.trecan.2017.08.006"},{"key":"94549_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta, Y. & Grabocka, E. Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761\u2013774 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"94549_CR8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/ijc.34225","volume":"151","author":"P Dias Carvalho","year":"2022","unstructured":"Dias Carvalho, P. et al. Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF\/C-MET axis. Int. J. Cancer. 151, 1810\u20131823 (2022).","journal-title":"Int. J. Cancer"},{"key":"94549_CR9","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.yexcr.2011.06.002","volume":"317","author":"S Velho","year":"2011","unstructured":"Velho, S. & Haigis, K. M. Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras. Exp. Cell. Res. 317, 2732 (2011).","journal-title":"Exp. Cell. Res."},{"key":"94549_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh, S., Gro\u00df, O., Brummer, T. & Zeiser, R. Immune modulatory effects of oncogenic KRAS in cancer. Nat. Commun. 11, 1\u201311 (2020).","journal-title":"Nat. Commun."},{"key":"94549_CR11","doi-asserted-by":"crossref","unstructured":"Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R. & Velho, S. Targeting the tumor microenvironment: an unexplored strategy for mutant KRAS tumors. Cancers (Basel) 11 (2019).","DOI":"10.3390\/cancers11122010"},{"key":"94549_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","volume":"78","author":"PD Carvalho","year":"2018","unstructured":"Carvalho, P. D. et al. KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment. Cancer Res. 78, 7\u201314 (2018).","journal-title":"Cancer Res."},{"key":"94549_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal. Transduct. Target. Ther. 6, 1\u201320 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"94549_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms222413193","volume":"22","author":"M Haidar","year":"2021","unstructured":"Haidar, M. & Jacquemin, P. Past and future strategies to inhibit membrane localization of the KRAS oncogene. Int. J. Mol. Sci. 22, 22 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"94549_CR15","doi-asserted-by":"crossref","unstructured":"Merz, V. et al. Targeting KRAS: the elephant in the room of epithelial cancers. Front. Oncol. 11 (2021).","DOI":"10.3389\/fonc.2021.638360"},{"key":"94549_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s41589-022-01065-9","volume":"18","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Guiley, K. Z. & Shokat, K. M. Chemical acylation of an acquired Serine suppresses oncogenic signaling of K-Ras (G12S). Nat. Chem. Biol. 18, 1177\u20131183 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"94549_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M. et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"94549_CR18","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima, E. C. et al. FDA approval summary: Sotorasib for KRAS G12C mutated metastatic NSCLC. Clin. Cancer Res. 28, 1482 (2022).","journal-title":"Clin. Cancer Res."},{"key":"94549_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"94549_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu, G., Pei, L., Xia, H., Tang, Q. & Bi, F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol. Cancer. 20, 1\u201317 (2021).","journal-title":"Mol. Cancer"},{"key":"94549_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","volume":"205","author":"J Neumann","year":"2009","unstructured":"Neumann, J., Zeindl-Eberhart, E., Kirchner, T. & Jung, A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205, 858\u2013862 (2009).","journal-title":"Pathol. Res. Pract."},{"key":"94549_CR22","doi-asserted-by":"crossref","unstructured":"Oya, Y., Imaizumi, K. & Mitsudomi, T. The next-generation KRAS inhibitors\u2026 What comes after sotorasib and adagrasib? Lung Cancer 194 (2024).","DOI":"10.1016\/j.lungcan.2024.107886"},{"key":"94549_CR23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0959-8049(20)31077-7","volume":"138","author":"ML Johnson","year":"2020","unstructured":"Johnson, M. L. et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur. J. Cancer 138, S2 (2020).","journal-title":"Eur. J. Cancer"},{"key":"94549_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23, 115\u2013124 (2022).","journal-title":"Lancet Oncol."},{"key":"94549_CR25","doi-asserted-by":"crossref","unstructured":"Ciardiello, D., Maiorano, B. A. & Martinelli, E. Targeting KRASG12C in colorectal cancer: the beginning of a new era. ESMO Open 8 (2023).","DOI":"10.1016\/j.esmoop.2022.100745"},{"key":"94549_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"Y Rona","year":"2023","unstructured":"Rona, Y. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44\u201354 (2023).","journal-title":"N. Engl. J. Med."},{"key":"94549_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cell.2011.12.033","volume":"148","author":"A Singh","year":"2012","unstructured":"Singh, A. et al. TAK1 Inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148, 639\u2013650 (2012).","journal-title":"Cell"},{"key":"94549_CR28","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41592-021-01291-4","volume":"18","author":"A Peirsman","year":"2021","unstructured":"Peirsman, A. et al. MISpheroID: A knowledgebase and transparency tool for minimum information in spheroid identity. Nat. Methods 18, 1294\u20131303 (2021).","journal-title":"Nat. Methods"},{"key":"94549_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","volume":"21","author":"C Hetz","year":"2020","unstructured":"Hetz, C., Zhang, K. & Kaufman, R. J. Mechanism, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell. Biol. 21, 421 (2020).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"94549_CR30","doi-asserted-by":"publisher","first-page":"eabn4180","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv, X. et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381, eabn4180 (2023).","journal-title":"Science"},{"key":"94549_CR31","doi-asserted-by":"crossref","unstructured":"Siwecka, N. et al. Dual role of Endoplasmic reticulum stress-mediated unfolded protein response signaling pathway in carcinogenesis. Int. J. Mol. Sci. 20 (2019).","DOI":"10.3390\/ijms20184354"},{"key":"94549_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pharmthera.2012.02.003","volume":"134","author":"AM Gorman","year":"2012","unstructured":"Gorman, A. M., Healy, S. J. M., J\u00e4ger, R. & Samali, A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol. Ther. 134, 306\u2013316 (2012).","journal-title":"Pharmacol. Ther."},{"key":"94549_CR33","doi-asserted-by":"crossref","unstructured":"Wen, J. H. et al. Cellular protein aggregates: formation, biological effects, and ways of elimination. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms24108593"},{"key":"94549_CR34","doi-asserted-by":"publisher","first-page":"101119","DOI":"10.1016\/j.arr.2020.101119","volume":"62","author":"S Francisco","year":"2020","unstructured":"Francisco, S., Ferreira, M., Moura, G., Soares, A. R. & Santos, M. A. Does proteostasis get lost in translation? Implications for protein aggregation across the lifespan. Ageing Res. Rev. 62, 101119 (2020).","journal-title":"Ageing Res. Rev."},{"key":"94549_CR35","doi-asserted-by":"crossref","unstructured":"Chen, G., Wei, T., Ju, F. & Li, H. Protein quality control and aggregation in the Endoplasmic reticulum: from basic to bedside. Front. Cell. Dev. Biol. 11 (2023).","DOI":"10.3389\/fcell.2023.1156152"},{"key":"94549_CR36","first-page":"eabn4180","volume":"381","author":"X Lv","year":"2024","unstructured":"Lv, X. et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science (1979) 381, eabn4180 (2024).","journal-title":"Science (1979)"},{"key":"94549_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/ATVBAHA.116.307922","volume":"37","author":"RF Wu","year":"2017","unstructured":"Wu, R. F. et al. RasGRF couples Nox4-dependent Endoplasmic reticulum signaling to Ras. Arterioscler. Thromb. Vasc Biol. 37, 98\u2013107 (2017).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"94549_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh, A. et al. A gene expression signature associated with \u2018K-Ras addiction\u2019 reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489\u2013500 (2009).","journal-title":"Cancer Cell"},{"key":"94549_CR39","doi-asserted-by":"crossref","unstructured":"Oliveira, S. M. et al. Fibroblasts promote resistance to KRAS Silencing in colorectal cancer cells. Cancers (Basel) 16 (2024).","DOI":"10.3390\/cancers16142595"},{"key":"94549_CR40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-14-1490","volume":"5","author":"E Chevet","year":"2015","unstructured":"Chevet, E., Hetz, C. & Samali, A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 5, 586\u2013597 (2015).","journal-title":"Cancer Discov"},{"key":"94549_CR41","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3752760\/v2","author":"F Martins","year":"2024","unstructured":"Martins, F. et al. KRAS Silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3752760\/v2 (2024).","journal-title":"Res. Sq"},{"key":"94549_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2172-10-10","volume":"10","author":"DP Granados","year":"2009","unstructured":"Granados, D. P. et al. ER stress affects processing of MHC class I-associated peptides. BMC Immunol. 10, 10 (2009).","journal-title":"BMC Immunol."},{"key":"94549_CR43","doi-asserted-by":"publisher","first-page":"101930","DOI":"10.1016\/j.jbc.2022.101930","volume":"298","author":"R Mercier","year":"2022","unstructured":"Mercier, R. & LaPointe, P. The role of cellular proteostasis in antitumor immunity. J. Biol. Chem. 298, 101930 (2022).","journal-title":"J. Biol. Chem."},{"key":"94549_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.09.011","author":"H Urra","year":"2024","unstructured":"Urra, H., Aravena, R., Gonz\u00e1lez-Johnson, L. & Hetz, C. The uprising connection between Endoplasmic reticulum stress and the tumor microenvironment. Trends Cancer. https:\/\/doi.org\/10.1016\/j.trecan.2024.09.011 (2024).","journal-title":"Trends Cancer"},{"key":"94549_CR45","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.cell.2016.12.004","volume":"168","author":"JR Cubillos-Ruiz","year":"2017","unstructured":"Cubillos-Ruiz, J. R., Bettigole, S. E. & Glimcher, L. H. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell 168, 692\u2013706 (2017).","journal-title":"Cell"},{"key":"94549_CR46","doi-asserted-by":"publisher","first-page":"188839","DOI":"10.1016\/j.bbcan.2022.188839","volume":"1878","author":"A Izadpanah","year":"2023","unstructured":"Izadpanah, A., Willingham, K., Chandrasekar, B., Alt, E. U. & Izadpanah, R. Unfolded protein response and angiogenesis in malignancies. Biochim. Biophys. Acta (BBA) Rev. Cancer 1878, 188839 (2023).","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"94549_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen, X. & Cubillos-Ruiz, J. R. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat. Rev. Cancer. 21, 71\u201388 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"94549_CR48","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41401-023-01053-2","volume":"44","author":"L Xu","year":"2023","unstructured":"Xu, L. et al. 143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models. Acta Pharmacol. Sin. 44, 1475\u20131486 (2023).","journal-title":"Acta Pharmacol. Sin"},{"key":"94549_CR49","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559\u2013572e7 (2019).","journal-title":"Cancer Cell"},{"key":"94549_CR50","doi-asserted-by":"crossref","unstructured":"Mugarza, E. et al. Therapeutic KRAS G12C Inhibition drives effective interferon-mediated antitumor immunity in Immunogenic lung cancers. Sci. Adv. 8 (2022).","DOI":"10.1126\/sciadv.abm8780"},{"key":"94549_CR51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov"},{"key":"94549_CR52","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"94549_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods. 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"94549_CR54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nmeth.1314","volume":"6","author":"EK Schmidt","year":"2009","unstructured":"Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat. Methods. 6, 275\u2013277 (2009).","journal-title":"Nat. Methods"},{"key":"94549_CR55","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94549-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:07:17Z","timestamp":1745500037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94549-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94549-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14329"}}